(Q42809906)

7 November 2017

0 references

Neuro-oncology, a decade of temozolomide and beyond (English)

1 reference

7 November 2017

0 references

3

Michael Weller

1 reference

7 November 2017

Roger Stupp

1

1 reference

7 November 2017

Monika Hegi

series ordinal

2

1 reference

7 November 2017

publication date

1 November 2010

1 reference

Expert Review of Anticancer Therapy

7 November 2017

published in

1 reference

7 November 2017

volume

10

1 reference

7 November 2017

issue

11

1 reference

7 November 2017

page(s)

1675-1677

1 reference

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

7 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Current and future developments in the use of temozolomide for the treatment of brain tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

MGMT promoter methylation in malignant gliomas: ready for personalized medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERA.10.161

21 January 2018

Identifiers

DOI

10.1586/ERA.10.161

1 reference

7 November 2017

1 reference